Glytech, Inc.

Taiji Shimoda

Hirofumi Ochiai

Keisuke Tazuru

Kazuhiro Fukae

Masatoshi Maeda

Kenta Yoshida

Katsunari Tezuka

Kazuyuki Ishii

Katsunori Tanaka

Hayato Saijo

Kenward Vong

[Problem] To provide a novel artificial protein catalyst that enables the protection of a catalyst from substances in vivo and has potential usefulness in therapeutic in vivo synthetic chemistry. [Solution] Provided is a complex of a protein and a catalyst selected from a metal catalyst or organic catalyst. In the complex according to the present invention, the protein is a protein having a hydrophobic pocket in the three-dimensional structure thereof, and the catalyst is housed in the hydrophobic pocket so that the catalyst is not or substantially not exposed to a hydrophilic environment.

Artificial protein catalyst

The object of the present invention is to provide a sugar chain-polypeptide complex that may form a transparent and homogeneous hydrogel in a broad pH. The present invention provides a sugar chain-polypeptide complex, characterized in that said polypeptide is a polypeptide comprising an amino acid sequence consisting of 8-34 amino acid residues in which polar and nonpolar amino acid residues are alternately arranged, and one or more sugar chains are bound to said polypeptide.

Sugar chain-polypeptide complex

[Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid.

Glycosylated polypeptide and drug composition containing said polypeptide

[Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino acids in a somatostatin or an analog thereof being replaced by glycosylated amino acids.

[Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino acids in a somatostatin or an analogue thereof being replaced by glycosylated amino acids.

Growing community of inventors

Kyoto, Japan

Taiji Shimoda